Physician profile
Umar Hayat
NPI 1730596388
$380.56
in general payments reported to CMS, 2019-2025
9 companies · $17.81 in 2025
The $17.81 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $125 · 2023: $202 · 2024: $36.09 · 2025: $17.81.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $255.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $127.98 | 2023 | Ocaliva |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $74.00 | 2022-2024 | Xifaxan, Plenvu |
| Merck Sharp & Dohme LLC | $38.38 | 2022 | |
| Abbvie INC. | $34.93 | 2022-2023 | |
| Qol Medical, LLC | $29.00 | 2023 | Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $26.46 | 2023 | Entyvio |
| Ipsen Biopharmaceuticals, INC | $17.85 | 2024 | Iqirvo |
| Janssen Biotech, INC. | $17.81 | 2025 | Tremfya |
| Ferring Pharmaceuticals INC. | $14.15 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Umar Hayat listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.